CD274 and osteosarcoma: Despite evidence that PD-L1 contributes to osteosarcoma growth and progression, clinical trials using checkpoint inhibitors have been associated with disappointing outcomes, raising doubts regarding the efficacy of targeting PD-L1 (15).